Index RUT P/E - EPS (ttm) -2.19 Insider Own 36.35% Shs Outstand 66.75M Perf Week -0.93%
Market Cap 68.89M Forward P/E - EPS next Y -1.08 Insider Trans -0.03% Shs Float 42.51M Perf Month -25.69%
Income -145.47M PEG - EPS next Q -0.30 Inst Own 66.03% Short Float 4.18% Perf Quarter -55.97%
Sales 18.58M P/S 3.71 EPS this Y 0.20% Inst Trans -1.86% Short Ratio 7.68 Perf Half Y -62.06%
Book/sh 1.56 P/B 0.68 EPS next Y 44.99% ROA -46.16% Short Interest 1.78M Perf Year -41.53%
Cash/sh 2.87 P/C 0.37 EPS next 5Y - ROE -86.50% 52W Range 0.75 - 4.65 Perf YTD -35.15%
Dividend Est. - P/FCF - EPS past 5Y -20.44% ROI -77.62% 52W High -76.99% Beta 2.68
Dividend TTM - Quick Ratio 6.34 Sales past 5Y -20.00% Gross Margin 72.66% 52W Low 42.67% ATR (14) 0.14
Dividend Ex-Date - Current Ratio 6.34 EPS Y/Y TTM -10.64% Oper. Margin -485.50% RSI (14) 33.42 Volatility 9.82% 11.19%
Employees 174 Debt/Eq 0.90 Sales Y/Y TTM 514.08% Profit Margin -782.87% Recom 1.86 Target Price 7.50
Option/Short Yes / Yes LT Debt/Eq 0.79 EPS Q/Q 46.51% Payout - Rel Volume 1.50 Prev Close 1.11
Sales Surprise 284.23% EPS Surprise 15.35% Sales Q/Q 252.00% Earnings Nov 06 AMC Avg Volume 231.15K Price 1.07
SMA20 -11.97% SMA50 -35.74% SMA200 -59.00% Trades
Volume 346,961 Change -3.60%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-19-23 Downgrade TD Cowen
Outperform → Market Perform
Nov-08-22 Initiated Canaccord Genuity
Buy
$9
Dec-14-21 Downgrade William Blair
Outperform → Mkt Perform
Jun-08-21 Initiated JMP Securities
Mkt Outperform
$40
Feb-24-21 Initiated William Blair
Outperform
Feb-18-21 Initiated Needham
Buy
$50
Jul-07-20 Initiated Wedbush
Outperform
$31
Jul-07-20 Initiated JP Morgan
Overweight
$28
Jul-07-20 Initiated Jefferies
Buy
$38
Jul-07-20 Initiated Cowen
Outperform
Nov-06-24 05:40PM
04:05PM
Oct-22-24 06:59AM
Sep-12-24 04:05PM
Aug-07-24 11:54PM
(InvestorPlace) -9.39%
+8.11%
07:35PM
Loading…
07:35PM
04:05PM
Aug-06-24 06:59AM
Jun-14-24 06:59AM
Jun-03-24 04:30PM
04:17PM
May-25-24 11:10PM
May-13-24 09:54PM
(InvestorPlace) -5.02%
+24.65%
05:15PM
04:05PM
06:59AM
Loading…
May-09-24 06:59AM
May-04-24 10:49AM
Apr-22-24 05:31PM
Apr-02-24 06:59AM
Mar-08-24 04:32AM
Mar-06-24 10:52PM
05:40PM
04:20PM
Feb-27-24 06:59AM
Jan-03-24 04:05PM
Dec-06-23 03:05AM
Nov-29-23 08:41AM
06:59AM
Nov-09-23 04:15PM
(GlobeNewswire) -11.11%
+10.58%
Oct-26-23 06:59AM
06:59AM
Loading…
Oct-18-23 06:59AM
Sep-19-23 07:30AM
Aug-03-23 08:49AM
07:30AM
Aug-02-23 07:05PM
04:15PM
May-31-23 07:30AM
May-10-23 06:05PM
04:15PM
May-09-23 04:15PM
Apr-11-23 07:30AM
Apr-10-23 09:40AM
Apr-05-23 07:30AM
Mar-24-23 03:02PM
Mar-23-23 10:43AM
07:29AM
07:00AM
Mar-21-23 04:15PM
Feb-27-23 07:30AM
Feb-24-23 07:18AM
Feb-23-23 04:28PM
Jan-03-23 04:30PM
Dec-05-22 09:55AM
Nov-17-22 09:55AM
Nov-03-22 04:15PM
Nov-01-22 08:07AM
Sep-22-22 07:30AM
Sep-20-22 07:30AM
Sep-17-22 08:12AM
Aug-04-22 05:45PM
04:15PM
Aug-02-22 04:15PM
Jul-18-22 07:30AM
Jul-11-22 09:55AM
Jun-21-22 08:30AM
Jun-02-22 07:30AM
May-25-22 06:37AM
May-05-22 07:05PM
04:15PM
Apr-05-22 07:30AM
Mar-25-22 12:00PM
10:00AM
Mar-02-22 07:30AM
Feb-24-22 04:20PM
(GlobeNewswire) +9.09%
+10.96%
Feb-10-22 07:30AM
Jan-05-22 07:30AM
Dec-28-21 07:37PM
Dec-19-21 09:37PM
Dec-16-21 11:02PM
06:38PM
07:01AM
Dec-14-21 06:30AM
12:38AM
Nov-10-21 04:20PM
Oct-22-21 07:30AM
Oct-21-21 04:05PM
Oct-15-21 07:30AM
Sep-30-21 11:12AM
Sep-17-21 08:34AM
Aug-11-21 04:20PM
Aug-03-21 07:30AM
Jul-14-21 07:30AM
Jul-08-21 07:30AM
Jun-19-21 05:55AM
Jun-09-21 07:30AM
May-27-21 07:30AM
May-12-21 04:20PM
Apr-27-21 04:35PM
Apr-08-21 07:30AM
Mar-21-21 05:20AM
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Howze Yalonda CHIEF LEGAL OFFICER Oct 15 '24 Option Exercise 2.42 3,347 8,100 15,169 Oct 17 04:05 PM Paone Antoinette CHIEF OPERATING OFFICER Jul 01 '24 Sale 2.74 6,719 18,410 13,807 Jul 03 04:34 PM Paone Antoinette CHIEF OPERATING OFFICER Jan 02 '24 Sale 1.62 2,445 3,961 5,828 Jan 03 04:35 PM Samayoa Phillip CHIEF STRATEGY OFFICER Jan 02 '24 Sale 1.62 2,445 3,961 107,256 Jan 03 04:35 PM
Index - P/E - EPS (ttm) -0.94 Insider Own 3.04% Shs Outstand 111.43M Perf Week -0.80%
Market Cap 4.42B Forward P/E - EPS next Y -1.49 Insider Trans -16.99% Shs Float 108.05M Perf Month -22.95%
Income -99.15M PEG - EPS next Q -0.27 Inst Own 73.78% Short Float 16.93% Perf Quarter -33.21%
Sales 0.00M P/S - EPS this Y -4.64% Inst Trans 1.73% Short Ratio 4.27 Perf Half Y -22.35%
Book/sh 8.18 P/B 5.03 EPS next Y -56.42% ROA -15.02% Short Interest 18.30M Perf Year 109.57%
Cash/sh 8.66 P/C 4.75 EPS next 5Y 40.00% ROE -15.50% 52W Range 17.23 - 99.41 Perf YTD 121.17%
Dividend Est. - P/FCF - EPS past 5Y -18.89% ROI -10.87% 52W High -58.60% Beta 0.90
Dividend TTM - Quick Ratio 36.47 Sales past 5Y 0.00% Gross Margin - 52W Low 138.89% ATR (14) 2.94
Dividend Ex-Date - Current Ratio 36.47 EPS Y/Y TTM -1.31% Oper. Margin - RSI (14) 32.74 Volatility 4.93% 5.15%
Employees 27 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 112.14
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q 0.35% Payout - Rel Volume 0.59 Prev Close 42.68
Sales Surprise - EPS Surprise 9.43% Sales Q/Q - Earnings Oct 23 AMC Avg Volume 4.29M Price 41.16
SMA20 -11.81% SMA50 -26.39% SMA200 -32.73% Trades
Volume 2,551,228 Change -3.56%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-02-24 Initiated Piper Sandler
Overweight
Nov-22-24 Initiated B. Riley Securities
Buy
$109
Nov-04-24 Reiterated H.C. Wainwright
Buy
$90 → $102
Sep-11-24 Initiated JP Morgan
Overweight
$80
Jun-27-24 Initiated Morgan Stanley
Overweight
$105
May-16-24 Upgrade Raymond James
Outperform → Strong Buy
$115 → $116
Mar-26-24 Reiterated Oppenheimer
Outperform
$116 → $138
Mar-07-24 Initiated Jefferies
Buy
$110
Feb-28-24 Reiterated Oppenheimer
Outperform
$46 → $116
May-31-23 Resumed ROTH MKM
Buy
$32
Mar-28-23 Reiterated Maxim Group
Buy
$15 → $25
Mar-17-23 Initiated Stifel
Buy
$22
Jul-29-21 Resumed BTIG Research
Buy
$20
May-25-21 Downgrade Raymond James
Strong Buy → Outperform
$27 → $12
Jun-05-20 Initiated BMO Capital Markets
Outperform
$14
May-05-20 Initiated Chardan Capital Markets
Buy
$15
May-01-20 Initiated BTIG Research
Buy
$9
Jul-16-19 Initiated Oppenheimer
Outperform
$12
Jun-25-19 Initiated Stifel
Buy
Mar-29-19 Upgrade SVB Leerink
Mkt Perform → Outperform
$10 → $21
Show Previous Ratings
Dec-26-24 05:50PM
Dec-24-24 11:31PM
12:20PM
Dec-23-24 10:30AM
07:22AM
06:26AM
Loading…
Dec-21-24 06:26AM
04:05AM
Dec-20-24 06:32PM
05:45PM
04:11PM
(Investor's Business Daily)
12:20PM
11:52AM
(Investor's Business Daily)
10:31AM
(Investor's Business Daily)
08:17AM
(Investor's Business Daily)
Dec-18-24 04:06PM
(Investor's Business Daily) -18.03%
+8.39%
01:54PM
Loading…
01:54PM
01:12PM
10:25AM
Dec-17-24 05:47AM
Dec-16-24 04:15AM
Dec-15-24 07:37AM
Dec-13-24 05:45PM
Dec-10-24 04:10AM
Dec-05-24 07:15AM
Dec-03-24 08:27AM
07:00AM
Nov-28-24 01:17PM
Nov-26-24 05:16PM
(Investor's Business Daily)
01:04PM
(Investor's Business Daily)
Nov-25-24 04:21AM
06:30AM
Loading…
Nov-23-24 06:30AM
Nov-22-24 04:17PM
(Investor's Business Daily)
11:31AM
08:00AM
(Investor's Business Daily)
Nov-21-24 04:46PM
Nov-20-24 01:26PM
Nov-19-24 04:03PM
Nov-18-24 04:45AM
Nov-17-24 07:05AM
Nov-16-24 05:30AM
Nov-15-24 04:05AM
Nov-13-24 04:06PM
(Investor's Business Daily) -9.14%
09:45AM
Nov-12-24 04:05PM
Nov-10-24 05:15AM
Nov-08-24 07:10AM
Nov-07-24 10:15AM
07:00AM
Nov-05-24 01:02PM
10:03AM
04:23AM
Nov-04-24 06:48PM
06:33PM
04:16PM
04:10PM
(Investor's Business Daily)
04:00PM
02:59PM
01:38PM
(The Wall Street Journal)
12:31PM
(Investor's Business Daily)
12:08PM
10:39AM
10:27AM
09:59AM
09:53AM
(Investor's Business Daily)
09:43AM
(The Wall Street Journal)
09:36AM
(Investor's Business Daily)
08:22AM
07:22AM
(Investor's Business Daily)
07:14AM
07:06AM
(Investor's Business Daily)
07:00AM
(The Wall Street Journal)
06:30AM
06:27AM
04:48AM
(Investor's Business Daily)
Nov-01-24 04:08PM
(Investor's Business Daily)
Oct-31-24 04:05PM
05:45AM
Oct-30-24 11:23AM
Oct-29-24 04:11PM
(Investor's Business Daily)
Oct-28-24 04:05PM
Oct-27-24 10:45AM
Oct-24-24 06:28PM
04:55PM
04:54PM
04:04PM
(Investor's Business Daily)
03:06PM
12:21PM
(Thomson Reuters StreetEvents)
09:48AM
(Investor's Business Daily)
09:17AM
08:20AM
03:10AM
Oct-23-24 04:05PM
Oct-18-24 05:45PM
03:04PM
Oct-17-24 08:30AM
Oct-16-24 05:50PM
04:05PM
Oct-14-24 04:05PM
(Investor's Business Daily)
09:30AM
05:32AM
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MACARTNEY LAWSON Director Nov 08 '24 Option Exercise 5.80 2,000 11,600 49,965 Nov 08 06:22 PM MACARTNEY LAWSON Director Nov 08 '24 Sale 68.67 2,000 137,333 47,965 Nov 08 06:22 PM LAWSON MACARTNEY Director Nov 08 '24 Proposed Sale 68.67 2,000 137,333 Nov 08 06:13 PM ZANTE GREG Chief Financial Officer Oct 28 '24 Option Exercise 7.49 94,001 704,282 281,053 Oct 28 09:48 PM ZANTE GREG Chief Financial Officer Oct 28 '24 Sale 76.61 131,687 10,089,164 149,366 Oct 28 09:48 PM GREG ZANTE Officer Oct 28 '24 Proposed Sale 78.03 131,687 10,275,537 Oct 28 04:37 PM Rouan Sarah Kathryn Director Oct 25 '24 Option Exercise 4.88 11,000 53,680 11,000 Oct 25 07:28 PM Rouan Sarah Kathryn Director Oct 25 '24 Sale 80.89 11,000 889,790 0 Oct 25 07:28 PM SINGLETON J MATTHEW Director Oct 25 '24 Option Exercise 4.48 16,000 71,680 25,500 Oct 25 07:27 PM SINGLETON J MATTHEW Director Oct 25 '24 Sale 79.50 16,000 1,272,000 9,500 Oct 25 07:27 PM Rouan Sarah Kathryn Director Oct 25 '24 Proposed Sale 80.86 11,000 889,430 Oct 25 04:10 PM SINGLETON J MATTHEW Director Oct 25 '24 Proposed Sale 79.47 16,000 1,271,479 Oct 25 04:01 PM SINGLETON J MATTHEW Director Sep 20 '24 Option Exercise 1.19 10,300 12,257 19,800 Sep 20 09:21 PM SINGLETON J MATTHEW Director Sep 20 '24 Sale 69.50 10,300 715,850 9,500 Sep 20 09:21 PM Lian Brian President & CEO Sep 20 '24 Option Exercise 7.77 166,130 1,290,830 2,521,057 Sep 20 09:20 PM Lian Brian President & CEO Sep 20 '24 Sale 70.83 216,130 15,308,553 2,304,927 Sep 20 09:20 PM Lian Brian Officer Sep 20 '24 Proposed Sale 18.41 216,130 3,978,372 Sep 20 04:29 PM SINGLETON J MATTHEW Director Sep 20 '24 Proposed Sale 69.50 10,300 715,850 Sep 20 04:13 PM Lian Brian President & CEO Aug 21 '24 Option Exercise 7.77 1,000 7,770 2,355,927 Aug 22 07:23 PM Lian Brian President & CEO Aug 21 '24 Sale 69.90 1,000 69,900 2,354,927 Aug 22 07:23 PM SINGLETON J MATTHEW Director Aug 21 '24 Option Exercise 1.19 5,700 6,783 15,200 Aug 22 07:23 PM SINGLETON J MATTHEW Director Aug 21 '24 Sale 69.72 5,700 397,430 9,500 Aug 22 07:23 PM Lian Brian Officer Aug 21 '24 Proposed Sale 69.90 1,000 69,900 Aug 21 04:30 PM SINGLETON J MATTHEW Director Aug 21 '24 Proposed Sale 69.72 5,700 397,404 Aug 21 04:18 PM Lian Brian President & CEO Aug 19 '24 Option Exercise 7.77 112,870 877,000 2,467,797 Aug 19 08:13 PM Lian Brian President & CEO Aug 19 '24 Sale 65.80 112,870 7,426,508 2,354,927 Aug 19 08:13 PM SINGLETON J MATTHEW Director Aug 19 '24 Option Exercise 3.33 16,000 53,280 25,500 Aug 19 08:11 PM SINGLETON J MATTHEW Director Aug 19 '24 Sale 62.22 16,000 995,453 9,500 Aug 19 08:11 PM Lian Brian Officer Aug 19 '24 Proposed Sale 65.79 112,870 7,425,717 Aug 19 08:00 PM SINGLETON J MATTHEW Director Aug 19 '24 Proposed Sale 62.21 16,000 995,360 Aug 19 07:47 PM SINGLETON J MATTHEW Director Aug 14 '24 Option Exercise 8.00 20,786 166,288 30,286 Aug 14 08:03 PM SINGLETON J MATTHEW Director Aug 14 '24 Sale 57.53 20,786 1,195,736 9,500 Aug 14 08:03 PM SINGLETON J MATTHEW Director Aug 14 '24 Proposed Sale 57.53 20,786 1,195,735 Aug 14 04:38 PM ZANTE GREG Chief Financial Officer Jul 30 '24 Sale 57.15 16,136 922,212 187,052 Jul 31 04:05 PM Lian Brian President & CEO Jul 30 '24 Sale 57.58 115,859 6,670,604 2,354,927 Jul 31 04:05 PM Mancini Marianna Chief Operating Officer Jul 30 '24 Sale 57.13 18,026 1,029,912 362,149 Jul 31 04:05 PM GREG ZANTE Officer Jul 30 '24 Proposed Sale 57.15 16,136 922,232 Jul 30 05:58 PM MARIANNA MANCINI Officer Jul 30 '24 Proposed Sale 57.13 18,026 1,029,888 Jul 30 05:56 PM BRIAN LIAN Officer Jul 30 '24 Proposed Sale 57.58 115,859 6,671,057 Jul 30 05:55 PM ZANTE GREG Chief Financial Officer May 03 '24 Option Exercise 4.86 34,249 166,285 241,610 May 03 08:51 PM ZANTE GREG Chief Financial Officer May 03 '24 Sale 74.69 66,756 4,986,008 174,854 May 03 08:51 PM Mancini Marianna Chief Operating Officer May 01 '24 Option Exercise 6.18 281,425 1,740,575 629,933 May 02 09:27 PM Mancini Marianna Chief Operating Officer May 01 '24 Sale 78.66 281,425 22,136,474 348,508 May 02 09:27 PM Lian Brian President & CEO Feb 09 '24 Sale 29.90 45,000 1,345,500 2,139,882 Feb 09 08:59 PM Lian Brian President & CEO Feb 08 '24 Option Exercise 3.76 189,079 711,367 2,404,882 Feb 08 07:40 PM Lian Brian President & CEO Feb 08 '24 Sale 26.87 269,079 7,230,784 2,184,882 Feb 08 07:40 PM Rouan Sarah Kathryn Director Feb 08 '24 Option Exercise 8.32 25,000 208,000 25,000 Feb 08 07:38 PM Rouan Sarah Kathryn Director Feb 08 '24 Sale 28.05 25,000 701,250 0 Feb 08 07:38 PM Lian Brian President & CEO Jan 31 '24 Option Exercise 1.23 85,000 104,550 2,349,882 Jan 31 08:39 PM Lian Brian President & CEO Jan 31 '24 Sale 24.71 85,000 2,100,750 2,264,882 Jan 31 08:39 PM Lian Brian President & CEO Jan 30 '24 Option Exercise 1.23 35,000 43,050 2,299,882 Jan 30 09:05 PM Lian Brian President & CEO Jan 30 '24 Sale 23.95 35,000 838,250 2,264,882 Jan 30 09:05 PM Rouan Sarah Kathryn Director Jan 19 '24 Option Exercise 8.32 30,000 249,600 30,000 Jan 19 08:35 PM Rouan Sarah Kathryn Director Jan 19 '24 Sale 23.05 30,000 691,500 0 Jan 19 08:35 PM ZANTE GREG Chief Financial Officer Jan 04 '24 Sale 17.90 15,000 268,500 180,730 Jan 04 09:35 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
